In the past week, VRAX stock has gone down by -0.48%, with a monthly gain of 15.08% and a quarterly surge of 77.59%. The volatility ratio for the week is 8.18%, and the volatility levels for the last 30 days are 12.74% for Virax Biolabs Group Ltd The simple moving average for the past 20 days is 4.54% for VRAX’s stock, with a 36.39% simple moving average for the past 200 days.
Is It Worth Investing in Virax Biolabs Group Ltd (NASDAQ: VRAX) Right Now?
The 36-month beta value for VRAX is at 1.87. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VRAX is 4.05M, and currently, shorts hold a 5.72% of that float. The average trading volume for VRAX on November 08, 2024 was 6.02M shares.
VRAX) stock’s latest price update
The stock price of Virax Biolabs Group Ltd (NASDAQ: VRAX) has surged by 8.42 when compared to previous closing price of 1.90, but the company has seen a -0.48% decline in its stock price over the last five trading sessions. prnewswire.com reported 2024-10-23 that LONDON, Oct. 23, 2024 /PRNewswire/ — Virax Biolabs Group Limited (NASDAQ: VRAX) (“Virax” or the “Company”), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into a distribution agreement with Europa Biosite to commercialize the company’s ImmuneSelect Research Use portfolio in the United Kingdom and Ireland through its wholly owned subsidiary Cambridge Bioscience. “ImmuneSelect is an important suite of profiling solutions for assessing adaptive immunity and we are pleased to partner with Europa Biosite, a leader in life science distribution across Europe,” said James Foster, CEO of Virax Biolabs.
VRAX Trading at -13.68% from the 50-Day Moving Average
After a stumble in the market that brought VRAX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.11% of loss for the given period.
Volatility was left at 12.74%, however, over the last 30 days, the volatility rate increased by 8.18%, as shares surge +15.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -57.70% lower at present.
During the last 5 trading sessions, VRAX fell by -0.48%, which changed the moving average for the period of 200-days by +106.00% in comparison to the 20-day moving average, which settled at $1.9700. In addition, Virax Biolabs Group Ltd saw 41.10% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for VRAX
Current profitability levels for the company are sitting at:
- -41.53 for the present operating margin
- 0.32 for the gross margin
The net margin for Virax Biolabs Group Ltd stands at -43.05. The total capital return value is set at -1.22. Equity return is now at value -92.92, with -88.04 for asset returns.
Based on Virax Biolabs Group Ltd (VRAX), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -27.85. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -241.7.
Currently, EBITDA for the company is -6.22 million with net debt to EBITDA at 0.56. When we switch over and look at the enterprise to sales, we see a ratio of 35.67. The receivables turnover for the company is 0.72for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 25.94.
Conclusion
In conclusion, Virax Biolabs Group Ltd (VRAX) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
